Brivanib alaninate - CAS 649735-63-7
Catalog number: B0084-146708
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C22H24FN5O4
Molecular Weight:
441.45
COA:
Inquire
Targets:
VEGFR
Description:
Brivanib alaninate is the alaninate ester of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression. Check for active clinical trials or closed clinical trials using this agent.
Synonyms:
BMS-582664; BMS582664; BMS 582664
MSDS:
Inquire
InChIKey:
LTEJRLHKIYCEOX-OCCSQVGLSA-N
InChI:
InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1
Canonical SMILES:
CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NN4C3=C(C(=C4)OCC(C)OC(=O)C(C)N)C
Current Developer:
Bristol-Myers Squibb.
1.New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials.
Qu K1, Huang Z2, Lin T1, Liu S1, Chang H3, Yan Z4, Zhang H4, Liu C1. Front Pharmacol. 2016 Jan 18;6:300. doi: 10.3389/fphar.2015.00300. eCollection 2015.
Tyrosine kinases (TKs) is a family of tyrosine protein kinases with important functions in the regulation of a broad variety of physiological cell processes. Overactivity of TK disturbs cellular homeostasis and has been linked to the development of certain diseases, including various fibrotic diseases. In regard to liver fibrosis, several TKs, such as vascular endothelial growth factor receptor, platelet-derived growth factor receptor, fibroblast growth factor receptor, and epidermal growth factor receptor kinases, have been identified as central mediators in collagen production and potential targets for anti-liver fibrosis therapies. Given the essential role of TKs during liver fibrogenesis, multitargeted inhibitors of aberrant TK activity, including sorafenib, erlotinib, imatinib, sunitinib, nilotinib, brivanib and vatalanib, have been shown to have potential for treating liver fibrosis. Beneficial effects are observed by researchers of this field using these multitargeted TK inhibitors in preclinical animal models and in patients with liver fibrosis.
2.Effect of milling temperatures on surface area, surface energy and cohesion of pharmaceutical powders.
Shah UV1, Wang Z1, Olusanmi D2, Narang AS2, Hussain MA2, Tobyn MJ3, Heng JY4. Int J Pharm. 2015 Nov 10;495(1):234-40. doi: 10.1016/j.ijpharm.2015.08.061. Epub 2015 Aug 24.
Particle bulk and surface properties are influenced by the powder processing routes. This study demonstrates the effect of milling temperatures on the particle surface properties, particularly surface energy and surface area, and ultimately on powder cohesion. An active pharmaceutical ingredient (API) of industrial relevance (brivanib alaninate, BA) was used to demonstrate the effect of two different, but most commonly used milling temperatures (cryogenic vs. ambient). The surface energy of powders milled at both cryogenic and room temperatures increased with increasing milling cycles. The increase in surface energy could be related to the generation of surface amorphous regions. Cohesion for both cryogenic and room temperature milled powders was measured and found to increase with increasing milling cycles. For cryogenic milling, BA had a surface area ∼ 5× higher than the one obtained at room temperature. This was due to the brittle nature of this compound at cryogenic temperature.
3.SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
Tai WT1,2, Hung MH3,4,5, Chu PY6,7, Chen YL8,9, Chen LJ1,2, Tsai MH1,2, Chen MH1,2, Shiau CW10, Boo YP1,2, Chen KF1,2. Oncotarget. 2016 Mar 5. doi: 10.18632/oncotarget.7923. [Epub ahead of print]
Pyruvate kinase M2 (PKM2) is known to promote tumourigenesis through dimer formation of p-PKM2Y105. Here, we investigated whether SH2-containing protein tyrosine phosphatase 1 (SHP-1) decreases p-PKM2Y105 expression and, thus, determines the sensitivity of sorafenib through inhibiting the nuclear-related function of PKM2. Immunoprecipitation and immunoblot confirmed the effect of SHP-1 on PKM2Y105 dephosphorylation. Lactate production was assayed in cells and tumor samples to determine whether sorafenib reversed the Warburg effect. Clinical hepatocellular carcinoma (HCC) tumor samples were assessed for PKM2 expression. SHP-1 directly dephosphorylated PKM2 at Y105 and further decreased the proliferative activity of PKM2; similar effects were found in sorafenib-treated HCC cells. PKM2 was also found to determine the sensitivity of targeted drugs, such as sorafenib, brivanib, and sunitinib, by SHP-1 activation. Significant sphere-forming activity was found in HCC cells stably expressing PKM2.
4.Systemic therapies for hepatocellular carcinoma.
Ge S1, Huang D. Drug Discov Ther. 2015 Oct;9(5):352-62. doi: 10.5582/ddt.2015.01047.
Hepatocellular carcinoma (HCC) is a common cancer with high incidence and mortality worldwide. The main treatments for HCC include radical hepatectomy, liver transplant, locoregional therapies, and systemic therapies. Systemic treatments include targeted agent treatment, chemotherapies, antiviral therapies, and nutritional treatments. According to the results of SHARP and ORIENTAL study, sorafenib became the standard first-line therapy since 2008 because of nearly three months of survival improvement in patients with advanced HCC. Subsequent studies on targeted agents found that neither sunitinib nor brivanib were superior to sorafenib as first-line therapy. After progression or intolerance of sorafenib, brivanib did not improve the overall survival (OS) compared with placebo as second-line therapy. Randomized controlled EACH study and retrospective AGEO study for systemic chemotherapy showed that oxaliplatin-based or gemcitabine-based regimen was effective for advanced HCC patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related VEGFR Products


CAS 284461-73-0 Sorafenib

Sorafenib
(CAS: 284461-73-0)

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.

CAS 894783-71-2 BIBF 1202

BIBF 1202
(CAS: 894783-71-2)

BIBF 1202 is the major in-vivo metabolite of BIBF 1120, which is an oral triple angiokinase inhibitor targeting VEGFR, PDGFR, FGFR. It is a related compound of ...

CAS 252916-29-3 Orantinib

Orantinib
(CAS: 252916-29-3)

TSU-68 (SU6668; Orantinib) is a novel multiple receptor tyrosine kinase inhibitor with IC50 of 2.1 μM, 8 nM and 1.2 μM for VEGF-R1, PDGF-Rβ and FGF-R1, respecti...

CAS 867331-82-6 TG 100801

TG 100801
(CAS: 867331-82-6)

TG 100801 is the prodrug of TG 100572, which is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kin...

CAS 934353-76-1 ENMD-2076

ENMD-2076
(CAS: 934353-76-1)

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has be...

CAS 1092788-83-4 PP121

PP121
(CAS: 1092788-83-4)

PP121 is a multitargeted dual receptor tyrosine kinases inhibitor. PP121 blocks the proliferation of tumor cells by direct inhibition of oncogenic tyrosine kin...

CAS 38101-59-6 H-Glu-Trp-OH

H-Glu-Trp-OH
(CAS: 38101-59-6)

H-Glu-Trp-OH inhibits VEGF, which may inhibit angiogenesis.

CAS 408502-06-7 KDR-in-4

KDR-in-4
(CAS: 408502-06-7)

A potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor (IC50= 7 nM)

Chemical Structure

CAS 649735-63-7 Brivanib alaninate

Quick Inquiry

Verification code

Featured Items